Marie Lindholm, Ph.D.Vice President, Molecular Design at Silence Therapeutics
As head of Molecular Design at Silence Therapeutics, Marie is leading a skilled team focusing on fine-tuning design of GalNAc-conjugated siRNA and exploring extra-hepatic siRNA targeting.
Marie got solid academic experience as a cardiovascular researcher in Sweden, UK, and US before stepping into the world of oligonucleotide therapeutics, starting with LNA oligonucleotide research at Santaris Pharma. When Santaris was acquired by Roche Marie was appointed Expert Scientist in Discovery Technology and Head of Targeted Delivery of oligonucleotide conjugates.
Marie has authored >60 patents and peer-reviewed scientific publications, many in the fields of oligonucleotide drug design, safety, and function.